Northwestern University: Carcinoma trials

The registry lists 27 Carcinoma studies with Northwestern University as lead sponsor. 1 are open to participants now and 17 have results posted.

Early Phase 1 1Phase 1 6Phase 2 15No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsRecruitingNCT05733000Phase 2
• Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04753216Phase 2Results posted
• sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate CancerStatus unknownNCT04033432Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland CancerActive, not recruitingNCT03146650Phase 2Results posted
• Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by SurgeryStatus unknownNCT03044730Phase 2Results posted
• Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the BreastCompletedNCT02993159Phase 2Results posted
• Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02901899Phase 2Results posted
• Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast CancerTerminatedNCT02892734Phase 2Results posted
• Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver CancerCompletedNCT02837029Phase 1Results posted
• Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder CancerCompletedNCT02808143Phase 1Results posted
• Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain MetastasisTerminatedNCT02774681Phase 2Results posted
• Nivolumab in Treating Patients With Metastatic Adrenocortical CancerTerminatedNCT02720484Phase 2Results posted
• Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing MastectomyCompletedNCT02314156Phase 2Results posted
• Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By SurgeryCompletedNCT01465659Phase 1/2Results posted
• Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant RecipientsCompletedNCT01127737Not applicableResults posted
• 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in SituCompletedNCT00952731Phase 2Results posted
• Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic SurgeryCompletedNCT00793169Results posted
• Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney CancerTerminatedNCT00727532Not applicableResults posted
• SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast CancerWithdrawnNCT05093387Phase 1
• Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical ResectionTerminatedNCT03812562Early Phase 1
• Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®TerminatedNCT03203837
• The PROMISE Study: Duavee in Women With DCISCompletedNCT02694809Phase 2
• Nanocytology Test to Evaluate Skin Cancer in High Risk PatientsCompletedNCT01905891Not applicable
• Basal Cell Carcinoma Recurrence After Mohs SurgeryCompletedNCT00882791
• Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular CarcinomaCompletedNCT00846131Phase 1
• Effect of the Subconscious on Mohs Micrographic SurgeryCompletedNCT00374062Not applicable
• Epirubicin and Celecoxib in Treating Patients With Hepatocellular CarcinomaCompletedNCT00057980Phase 1/2